Cycle Pharmaceuticals: 3D printed orphan drugs to hit market in 2-3 years

Cambridge-based Cycle Pharmaceuticals has just announced its strategy to harness 3D printing technology as a chief means of producing prescription drugs by way of a new partnership with Aprecia Pharmaceuticals. The partnership will see Cycle develop and commercialise 3D printed drugs for rare diseases, also known as 'orphan drugs.'